Keytruda accounted for more than 50% of Merck’s total pharmaceutical revenues in the first nine months of the fiscal year, underscoring its central role in the company’s top‐line growth. In Q3, Keytruda sales growth decelerated to approximately 5% year-over-year, down from double-digit growth rates recorded earlier in the year. This slowdown was attributed to increased competition in frontline lung and melanoma indications, as well as inventory adjustments in key international markets.

With Q3 momentum softer than expected, investors are closely watching Merck’s Q4 guidance and underlying Keytruda demand. Consensus forecasts peg Q4 Keytruda growth at mid-single digits, driven by continued uptake in new indications such as adjuvant colorectal and high-risk early‐stage cancers. Analysts will be monitoring any updates on pricing pressure in the U.S. reimbursement environment and inventory levels in China, where Keytruda has recently gained expanded label indications.

Merck’s late-stage pipeline includes multiple Phase III trials pairing Keytruda with novel agents, including TIGIT inhibitors and next-generation targeted therapies. Positive readouts from these studies over the next 12 months could bolster Keytruda’s market share against competitors like Roche’s Tecentriq and Bristol Myers Squibb’s Opdivo. Investors are also evaluating the potential impact of pipeline setbacks or regulatory decisions on Merck’s broader oncology franchise.